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Background: Early-onset pre-eclampsia with raised blood pressure and protein in the urine before 34 weeks’
gestation is one of the leading causes of maternal deaths in the UK. The benefits to the child from prolonging the
pregnancy need to be balanced against the risk of maternal deterioration. Accurate prediction models of risks are
needed to plan management.
Methods: We aim to undertake a multicentre prospective cohort study (Prediction of Risks in Early onset Pre-eclampsia
(PREP)) to develop clinical prediction models in women with early-onset pre-eclampsia, for risk of adverse maternal
outcomes by 48 h and by discharge. We will externally validate the models in two independent cohorts with 634 and
216 women. In the secondary analyses, we will assess risk of adverse fetal and neonatal outcomes at birth and by
discharge.
Discussion: The PREP study will quantify the risk of maternal complications at various time points and provide
individualised estimates of overall risk in women with early-onset pre-eclampsia to plan the management.
Trial registration: ISRCTN registry, ISRCTN40384046
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Pre-eclampsia is a multisystem disorder in pregnancy
associated with hypertension and proteinuria [1–3] and
occurs before 34 weeks in 1% of women, so called
early-onset pre-eclampsia [4, 5]. In the UK, hypertensive
disease in pregnancy remains a leading cause of direct
maternal deaths and contributes to about 20% of all
stillbirths [6].
With an increased risk of maternal complications and
20-fold higher maternal mortality, early-onset pre-* Correspondence: n.marlin@qmul.ac.uk
2Pragmatic Clinical Trials Unit, Barts and the London School of Medicine and
Dentistry, Queen Mary University of London, London, UK
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This artic
International License (http://creativecommons
reproduction in any medium, provided you g
the Creative Commons license, and indicate if
(http://creativecommons.org/publicdomain/zeeclampsia is considered to be pathophysiologically
different from the late-onset disease [7–9]. The only
known cure is delivery of the baby and placenta. How-
ever, fetal and neonatal benefits from delaying the
pregnancy need to be balanced against the risk of
multisystem dysfunction in the mother.
Although the proportion of women with early-onset
pre-eclampsia is only 1% of all pregnancies, the com-
plexity of the treatment gives rise to large health care
costs [4, 5]. Women are often admitted to tertiary care,
and with a third experiencing complications, a stay in an
intensive care facility may become necessary [10].
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caps arising as a result of prematurity.
One of the key recommendations in the last
CEMACH (Confidential Enquiries into Maternal and
Child Health) (now known as Centre for Maternal and
Child Enquiries (CMACE)) report is the need to adopt
an early warning system to help in the timely recogni-
tion, referral and treatment of women who have or are
developing critical conditions [6]. Early identification
of mothers with early-onset pre-eclampsia at risk of
complications, and their risks for these at various time
points after diagnosis, will allow clinicians to make
decisions on commencing interventions such as admin-
istration of steroids and, if needed, in utero transfer to a
tertiary unit. In mothers considered to be of low risk,
they can be monitored as an outpatient, and delivery
may be delayed to lower the risk of perinatal complica-
tions from prematurity.
We aim to develop prediction models to quantify the
overall risk of adverse maternal outcomes in women
with early-onset pre-eclampsia and at various time
points after diagnosis.
Methods/design
The Prediction of Risks in Early onset Pre-eclampsia
(PREP) study will be developed using existing recom-
mendations on prognostic research model development
and validation [11–13] and reported in line with the
Transparent Reporting of a multivariable prediction
model for Individual Prognosis Or Diagnosis (TRIPOD)
statement [14]. Ethical approval for the study was
received from the NRES Committee West Midlands
(approval number 11/WM/0248), and the study was
registered on ISRCTN registry as per the requirements
set out by the World Health Organization (WHO)
International Clinical Trials Registry Platform (ICTRP)
and the International Committee of Medical Journal
Editors (ICMJE) [15] guidelines with registration number
ISRCTN40384046 [16].
Objectives
The primary objectives are to develop and internally
validate a prediction model in women admitted with
early-onset pre-eclampsia from 20 weeks and 0 day to
33 weeks and 6 days of gestation, for assessment of the
risk of adverse maternal outcomes at 48 h and by dis-
charge. The 48 h of time interval was chosen to reflect
the time recommended for delivery after administration
of steroids to lower risks of respiratory distress in new-
borns. This time period is also considered to be the
optimal duration to make decisions on timing and place
of delivery and consider in utero transfer to a tertiary
care unit if needed. The model will be externally
validated in two independent datasets of patients with adiagnosis of early-onset pre-eclampsia. Our secondary
objective is to assess the risk of adverse fetal and neo-
natal outcomes at birth and at any time until discharge.
Study design and conduct
PREP is a prospective, multicentre, observational cohort
study involving secondary and tertiary care obstetric units
in England and Wales. All consecutive women with a
suspected or confirmed diagnosis of pre-eclampsia
before 34 weeks of gestation will be approached to
take part in the study by research midwives and clini-
cians in antenatal clinics, wards, day assessment units
and delivery suites. Clinicians managing the women
will be requested to complete the Clinicians Management
Plan at baseline to assess the reasons for planned manage-
ment. The predictors evaluated in the PREP prediction
model are routinely performed as part of standard clinical
practice in women admitted with early-onset pre-eclampsia.
The PREP study does not influence the management
of these patients.
Inclusion criteria
Women aged 16 years or over and a diagnosis of
new-onset or superimposed pre-eclampsia at gesta-
tional age between 20 + 0 and 33 + 6 weeks will be
considered for inclusion in the study. Women with a
diagnosis of HELLP (haemolysis, elevated liver enzymes,
low platelets) syndrome and those with one episode of
eclamptic seizures without hypertension or proteinuria
will be considered for inclusion. All women will be
required to provide written informed consent and must be
capable of understanding the information provided. The
definitions for the diagnosis of pre-eclampsia are provided
in Table 1.
Exclusion criteria
Women will be excluded if any of the outcomes (includ-
ing recurrent eclamptic seizures) occurs prior to testing
or if informed consent could not be obtained on time
or if the mother does not have a good understanding
of spoken and written English and a translator is
unavailable.
Candidate variables for inclusion in the model
Candidate predictor variables will be obtained from pa-
tient demographic characteristics and from clinical as-
sessment including clinical history, examination and
investigations. The predictors will be clearly defined and
standardised to ensure reproducibility and enhance gen-
eralisability and application of study results to practice.
Data will also be collected on any interventions applied
between recruitment and outcome onset that may mod-
ify the outcome.
Table 1 Definition of the inclusion criteria for recruitment into the PREP study
Condition Definition
New-onset pre-eclampsia New-onset hypertension (systolic BP ≥140 mmHg or diastolic BP ≥90 mmHg on 2 occasions
4–6 h apart in women) after 20 weeks of pregnancy and new-onset proteinuria (≥2+ in urine
dipstick or PCR of greater than 30 mg/mmol or 300 mg of protein excretion in 24 h) [37]
Suspected pre-eclampsia New-onset hypertension (systolic BP ≥140 mmHg or diastolic BP ≥90 mmHg on 2 occasions
4–6 h apart in women) after 20 weeks of pregnancy and 1+ proteinuria on urine dipstick
Superimposed pre-eclampsia
-
In women with chronic hypertension and no
proteinuria before 20 weeks’ gestation
New-onset proteinuria (as defined previously)
-
In women with significant proteinuria before
20 weeks’ gestation
Elevated serum alanine aminotransferase concentration (>70 U/L) or worsening hypertension
(either 2 diastolic BP of at least 110 mmHg 4 h apart or 1 diastolic measurement of at least
110 mmHg if the woman had been treated with an anti-hypertensive drug), plus one of the
following: increasing proteinuria, persistent severe headaches or epigastric pain
HELLP syndrome Haemolysis, elevated liver enzymes, and low platelets syndrome: presence of haemolysis
based on examination of the peripheral smear, elevated indirect bilirubin levels or low serum
haptoglobin levels in association with significant elevation in liver enzymes and a platelet
count below 100,000/mm3 after ruling out other causes of haemolysis and thrombocytopenia
1 episode of eclamptic seizures without
hypertension or proteinuria
Other neurological conditions of seizures have been excluded
Table 2 List of candidate predictor variables to be evaluated in
the PREP study
Maternal characteristics
Maternal age at diagnosis (years)
Gestational age at diagnosis (weeks)
Number of fetuses in pregnancy at time of consent (1, 2, 3)
History
Summary score for medical history—1 point for each of the
following: pre-existing hypertension, renal disease, diabetes mellitus,
autoimmune disease, previous history of pre-eclampsia (0, 1, 2 or more)
Symptoms
Headache and/or visual disturbance (yes/no)
Epigastric pain, nausea and/or vomiting (yes/no)
Chest pain and dyspnoea (yes/no)
Bedside examination and tests
Systolic blood pressure (mmHg, highest measurement over 6 h)
Diastolic blood pressure (mmHg, highest measurement over 6 h)
Clonus (yes/no)
Exaggerated tendon reflexes (yes/no)
Abnormal oxygen saturation (<95% on air) (yes/no)
Urine dipstick (0, 1+, 2+, 3+, 4+ or more)
Laboratory tests
Haemoglobin (g/L)
Platelet count (× 109/L)
ALT (IU/L)
Serum uric acid (μmol/L)
Serum urea (mmol/L)
Serum creatinine (μmol/L)
Urine protein-creatinine ratio (PCR) (mg/mmol)
Management at baseline
Administration of oral and/or parenteral anti-hypertensives (ongoing
or commenced within 1 day of diagnosis) (yes/no)
Administration of magnesium sulphate (commenced before or within
1 day of diagnosis) (yes/no)
Additional factors for fetal model only
Uterine artery Doppler (normal/abnormal)
Liquor volume (normal/abnormal)
CTG findings (normal/abnormal)
Estimated fetal weight <10th centile (yes/no)
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considered in the prediction model, based on the most
promising predictor variables as identified with our
previous systematic review [17–22]. The full list of
variables to be evaluated for prediction of maternal and
fetal outcomes is provided in Table 2.
Outcome measures
The primary outcome is a composite adverse maternal
outcome including maternal neurological, haemato-
logical, cardiorespiratory, hepatic and renal complica-
tions and death. We prioritised the outcomes for clinical
importance using a Delphi survey of researchers and
clinicians. Prior to the analysis, after discussion with the
independent Study Steering (SSC) and Data Monitoring
(DMC) Committees, we included delivery before 34 weeks
as a component of maternal composite outcome to
minimise bias due to treatment paradox [23]. The
secondary outcome is a composite adverse fetal out-
come (Table 3).
Sample size considerations
From our systematic reviews [17], 20% of women with
early-onset pre-eclampsia are expected to have adverse
maternal outcomes at any time before discharge. Rules
of thumb for fitting multivariate models suggest about
10 events for every variable are required to reduce issues
with overfitting, and we will work within this constraint
[24–26]. We initially planned to examine 10 predictor
variables and hence planned to recruit 500 women.
However, the event rate was lower than predicted, so we
revised our plan to recruit sufficient women to obtain
100 events. Subsequent to the inclusion of delivery
Table 3 Components of the maternal and fetal composite outcomes
Outcome Definition
Maternal outcomes
Mortality Maternal death at any time in pregnancy after delivery until discharge
Hepatic dysfunction INR >1.2 indicative of DIC in the absence of treatment with warfarin. (DIC is defined as having both
abnormal bleeding and consumptive coagulopathy (i.e. low platelets, abnormal peripheral blood film, or
one or more of the following: increased INR, increased PTT, low fibrinogen, of increased fibrin
degradation products that are outside normal non-pregnancy ranges).)
Hepatic haematoma or rupture Blood collection under the hepatic capsule as confirmed by ultrasound or laparotomy
Glasgow coma score <13 From the GCS scoring system [39]
Stroke Acute neurological event with deficits lasting longer than 48 h
Cortical blindness Loss of visual acuity in the presence of intact papillary response to light
RIND Cerebral ischaemia lasting longer than 24 h but less than 48 h revealed through clinical examination
Retinal detachment Separation of the inner layers of the retina from the underlying RPE (choroid) and is diagnosed by
ophthalmological examination
Acute renal insufficiency For women with an underlying history of renal disease: defined as creatinine >200 μM; for patients with
no underlying renal disease: defined as creatinine >150 μM
Dialysis Including haemodialysis and peritoneal dialysis
Transfusion of blood products Includes transfusion of any units of blood products: FFP, platelets, RBCs, cryo or whole blood
Positive ionotropic support The use of vasopressors to maintain a systolic blood pressure >90 mmHg or mean arterial pressure
>70 mmHg
Myocardial ischaemia/infarction ECG changes (ST segment elevation or depression) without enzyme changes and/or any one of the
following: (1) development of new pathologic Q waves on serial ECGs. The patient may or may not
remember previous symptoms. Biochemical markers of myocardial necrosis may have normalised,
depending on the length of time that has passed since the infarct developed. (2) Pathological findings of
an acute, healed or healing MI. (3) Typical rise and gradual fall (troponin) or more rapid rise and fall (CK-
MB) of biochemical markers of myocardial necrosis with at least one of the following: (a) ischaemic
symptoms; (b) development of pathologic Q waves on the ECG; (c) ECG changes indicative of ischaemia
(ST segment elevation or depression) or (d) coronary artery intervention (e.g. coronary angioplasty)
Require >50% oxygen for greater than
1 h
Oxygen given at greater than 50% concentration based on local criteria for longer than 1 h
Intubation other than for caesarean
section
Intubation maybe by ventilation, electrical impedance tomography or continuous positive airway
pressure
Pulmonary oedema Clinical diagnosis with x-ray confirmation or requirement of diuretic treatment and SaO2 <94%
Postpartum haemorrhage >1 L of blood loss after delivery
Early preterm delivery Delivery at gestational age of less than 34 weeks
Fetal outcomes
Perinatal or infant mortality Death of a fetus or neonate. Infant mortality is the death of a child less than 1 year of age
Bronchopulmonary dysplasia Oxygen requirement at 36 weeks’ corrected gestation unrelated to an acute respiratory episode
Necrotising enterocolitis including only
Bell’s stage 2 or 3
Evidence of pneumotosis intestinalis on abdominal x-ray and/or surgical intervention
Grade III/IV intraventricular
haemorrhage
Bleeding into the brain’s ventricular system, where the ventricles are enlarged by the accumulated blood
or bleeding extends into the brain tissue around the ventricles
Cystic periventricular leukomalacia Softening and necrosis in the hemispheric white matter in newborns that may result from impaired
perfusion at the interface between the ventriculopetal and ventriculofugal arteries
Stage 3–5 retinopathy of prematurity Abnormal blood vessel development in the retina of the eye, where blood vessel growth is severely
abnormal, where there is a partially or totally detached retina
Hypoxic ischaemic encephalopathy Apgar score ≤5 at 10 min and/or pH 7.00 in the first 60 min of life and/or base deficit ≥−16 in the first
60 min associated with an abnormal consciousness level (lethargy, stupor or coma) and seizures and/or
poor/weak suck and/or hypotonia and/or abnormal reflexes
Adapted from the PIERS study
INR international normalised ratio, DIC disseminated intravascular coagulation, PTT partial thromboplastin time, GCS Glasgow Coma Scale, RIND reversible
ischaemic neurologic deficit, RPE retinal pigment epithelium, FFP fresh frozen plasma, RBCs red blood cells, cryo cryoprecipitate, ECG electrocardiography
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come, we revised our plan to include 22 candidate pre-
dictor variables, which was approved by the independent
study Committees.
Statistical analysis
We will develop two prediction models: a survival model
for adverse maternal outcomes at various time points
from diagnosis up to 34 weeks of gestation, including by
48 h after admission, and a logistic model for adverse
maternal outcomes by discharge. These will both be de-
veloped using a general methodological and statistical
framework as outlined below.
Model development, apparent performance assessment and
internal validation
The predictors of adverse maternal outcomes will be
identified to develop and externally validate a simple, in-
terpretable and clinically applicable prediction model
with face validity. We will use a transparent process that
implements appropriate statistical methods and adheres
to current methodological recommendations.
A backwards selection procedure will be used to de-
cide which of the candidate predictor variables should
be included in the final prediction model (with p < 0.15
taken conservatively to warrant inclusion). Continuous
variables will be kept as continuous in the model (rather
than dichotomising), to avoid a loss of power [27, 28].
Non-linear trends will also be considered using the mul-
tivariable fractional polynomial procedure [29, 30],
which uses multivariable models to eliminate weaker
predictors and identify transformations of continuous
predictors that best predict outcome. Large amounts of
missing variable data are not expected, but some will in-
evitably occur, with not all patients providing all vari-
ables of interest. Multiple imputation will be used to
impute, with 5 imputations, under a missing at random
assumption, missing values so as to avoid excluding
patients from the analysis [27].
For survival analysis, failure event is defined as an
adverse outcome or delivery occurring before 34 weeks
of gestation. We will use a flexible parametric survival
model via the Royston-Parmar approach [31–33], with
the cumulative baseline hazard scale modelled using
restricted cubic splines. The number of knots will be
chosen by visual inspection. For the binary adverse
maternal outcome by discharge, a logistic regression-
modelling framework will be undertaken with the
logit probability of an adverse outcome being the re-
sponse variable.
We will assess the apparent performance of the fitted
models for discrimination using the C-statistic (Harrell’s
C-statistic from the survival model and AUC from the
logistic model), with 95% confidence interval, averagingacross the same imputed datasets that were used to gen-
erate the model. A C-statistic close to 1 indicates excel-
lent discrimination and 0.5 indicates no discrimination
beyond chance. The calibration performance of the
model (fit of observed to expected risk across all individ-
uals) will be assessed by checking whether the calibra-
tion slope is 1. As the model will be developed in the
same data, perfect agreement is expected on average
across the imputed datasets.
Non-parametric bootstrapping will be used to intern-
ally validate and examine the potential for overfitting of
our developed models, by repeating the variable selec-
tion procedure in 100 bootstrap datasets from each of
the 5 multiple imputation datasets, providing a total of
500 datasets. This leads to a new final model being pro-
duced in each of the bootstrap samples. We will average
the difference in the performance of the models to ob-
tain a single estimate of optimism for the C-statistic and
the calibration slope. The optimism-adjusted perform-
ance statistics will be obtained by subtracting the above
estimate of optimism from the original apparent per-
formance statistics. The optimism-adjusted calibration
slope will be taken as the uniform shrinkage, and the
final models will be corrected by this shrinkage factor.
External validation
We will externally validate (as far as possible) the
models in patients admitted with a diagnosis of early-
onset pre-eclampsia in two prospective datasets: The
Pre-eclampsia Eclampsia TRial Amsterdam (PETRA),
Netherlands, and Pre-eclampsia Integrated Estimate of
RiSk for mothers (PIERS), Canada. We will compare the
predicted number of events from our model with the ob-
served events in the external datasets to assess calibra-
tion for the logistic model and compare the predicted
with the observed survival function for the survival
model (as described above). We will also calculate the
C-statistic curve to assess discriminatory ability.
The models we develop (which use data from women
diagnosed with pre-eclampsia) will also be tested in
women defined with suspected pre-eclampsia (urine
dipstick 1+ on admission but normal 24-h proteinuria,
<300 mg/24 h and normal PCR <30 mg/mmol). Such
women will have been identified from our recruitment
process, and by checking the calibration and discrimin-
ation of our models for such patients, we can examine
the potential generalisability to a broader set of women.
Discussion
Pre-eclampsia and its complications are still considered
to be one of the leading causes of maternal and fetal
morbidity and mortality; the condition utilises a large
proportion of NHS resources. Accurate prediction and
early management can significantly improve these
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rently do not have the evidence on which they can base
their recommendations.
Timely prediction of complications in women with
early-onset pre-eclampsia involves the use of a combin-
ation of maternal characteristics, symptoms, physical
signs and investigations [21]. These ‘tests’ are to some
extent haphazardly performed in all units, due to the
absence of a structured approach. The most important
determinant of perinatal outcome is gestational age, with
more than half the chance of intact fetal survival when
this is more than 27 weeks and the birth weight is more
than 600 g [34].
A recent Cochrane review [10] has shown that expect-
ant management reduced risk of fetal and neonatal com-
plications without increase in maternal complications.
Clinicians are reluctant to promote expectant manage-
ment due to uncertainties around the scale of maternal
risk. One of the main reasons for this lack of confidence
in applying risk scores in practice is the absence of suffi-
cient evidence to show the reproducibility and transport-
ability of the model in a different population [11]. A
good performing prediction model is one that is accur-
ate, validated in populations and datasets external to
those used to develop the model, widely applicable in
practice, and acceptable to patients and ultimately im-
proves clinical outcomes by helping clinicians and pa-
tients make more informed decisions. With very small
numbers of cases and events per variable, early-onset
pre-eclampsia contributed little to current published
models [8, 35, 36].
It is currently difficult to identify those mothers with
early-onset pre-eclampsia who are at increased risk of
developing complications, and this risk cannot be
graded. There is a need for a prognostic model to in-
clude the predictive role of more than one test results
on the outcome with individualised risk assessment.
Provision of individualised risk estimates for adverse
maternal outcomes through the PREP study will help
clinicians make suitable decisions after discussion with
the parents.
Ideally, to develop a prediction model, we would like
to observe outcomes in a cohort of women who receive
no clinical management at all to be able to predict the
likelihood of an adverse outcome independent of clinical
management. Clearly, this is unethical and all women
who present with pre-eclampsia receive clinical manage-
ment, but such clinical decisions also affect maternal
outcomes. Thus, in the development of our prediction
model, we must recognise the importance of accounting
for current clinical management; however, this is
currently an under-researched methodological issue. By
including effective treatment measures such as use of
anti-hypertensives and magnesium sulphate predictorvariables, and delivery before 34 weeks as a component
of the composite outcome, we plan to negate some of
the bias arising from treatment paradox in prediction
models [23].
There is no obvious single outcome measurement that
determines clinical management in early-onset pre-
eclampsia. As the risk of more than one outcome needs
evaluation simultaneously, we have chosen a composite
measure consisting of several complications [37]. The
composite outcomes are constructed by including those
components whose underlying biology is similar [38].
To show that the PREP prognostic model is valuable,
it is not sufficient to show that it successfully predicts
outcome in the initial development data even after hav-
ing it being internally validated. We need evidence that
the model performs well for other (external) patients.
The resulting geographical and domain validation will
enable us to assess the prognostic performance and the
generalisability of the model.
Our prediction model plans to use rigorous statistical
methods to develop the model and assess accuracy;
undertake a formal validation in external datasets (PIERS
and PETRA); use unambiguous definitions of predictors
and reproducible measurements using methods available
in clinical practice; adjust for current clinical manage-
ment; obtain input from patient focus groups and pro-
duce personalised estimates of risk, which enable
patients and clinicians to make more informed decisions
on management aspects like continuing the pregnancy
or delivery of a preterm baby.
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